Clinipace Worldwide, a Research Triangle Park, NC-based digital clinical research organization (dCRO), closed a $50m round of debt and equity financing.
The round was led by Virgo Investment Group, and Crestline Investors, Inc., with participation from existing investors Morgan Stanley Expansion Capital, Hatteras Venture Partners, Harbert Venture Partners and Mario Family Funds.
The company plans to use the capital to continue building its therapeutic expertise and to further expand its capacity to deliver services to its clients.
Led by Jeff Williams, CEO, Clinipace Worldwide is a digital contract research organization (dCRO) featuring a technology-amplified CRO service model to serve the needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology and medical device firms. The company leverages its proprietary TEMPO™ eClinical platform and a team of experts with knowledge in therapeutic areas such as cardiovascular and metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines, to assist life science firms in executing regulatory strategies, clinical development, and post-approval research programs.
Clinipace, which employs 700 global staff, has managed over 1,500 clinical research studies, activated over 23,000 sites, enrolled over 330,000 subjects and managed over 300 regulatory and strategic development engagements. The company has additional domestic operations in Overland Park, KS and Boulder, CO. Additional offices are located across the globe in Switzerland, Germany, United Kingdom, Taiwan, China, South Korea, Hong Kong, Vietnam, Singapore, Malaysia, Brazil, Argentina, Israel and India.